RxDoctor Payments Data

Cheryl McNeil

Family · South Burlington, VTNPI 1992019475

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,176in general payments, 2019–2025

Across 85 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$397
  • Boston Scientific$261
  • Boehringer Ingelheim$217
  • Merck$176
  • Pfizer$171
  • Actelion Pharmaceuticals US, Inc.$148
  • plus $805 from 14 others

What the payments were for

  • Food & beverage$2,07695%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,176 in reported general payments places this provider in the 95th percentile of 75 family providers in Vermont.

See all family providers in Vermont

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban18$13,215
EliquisApixaban12$11,676
Amlodipine Besylate35$377
Metoprolol Succinate19$329
ClopidogrelClopidogrel Bisulfate34$215
Carvedilol19$193
Atorvastatin Calcium14$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$114$13,21518 claims
PfizerEliquis$171$11,67612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 family providers in Vermont.

Other family in South Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →